TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02571725
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
Study: NCT01255722
Drug: iobitridol
Normalized name: iobitridol
DrugBank: Iobitridol (DB12407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV injection
Study: NCT01255722
Drug: iopromide
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV injection
Study: NCT01255722
Drug: iomeprol
Normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV injection
Study: NCT03113825
Drug: AVB-620
Normalized name: AVB-101
DrugBank: AVB-101 (DB18416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB-620 will be administered IV before the surgical procedure.
Study: NCT02519387
Drug: Buprenorphine Transdermal Patch
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02392871
Drug: Dabrafenib and trametinib (combination)
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
Study: NCT06190691
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01825876
Drug: Evacetrapib
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01186224
Drug: Plerixafor and G-CSF
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily.
Study: NCT01825876
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00971685
Drug: Lenalidomide and dexamethasone
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
Study: NCT00611039
Drug: Darunavir 900mg + ritonavir 100 mg once a day
Normalized name: ritonavir 100 MG
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir 900mg + ritonavir 100 mg once a day
Study: NCT00611039
Drug: Darunavir 600mg + ritonavir 100mg twice day
Normalized name: darunavir 600 MG
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir 600mg + ritonavir 100mg twice day
Study: NCT01252238
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
Study: NCT00132106
Drug: phentolamine
Normalized name: Phentolamine
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01252238
Drug: Valsartan and Aliskiren
Normalized name: valsartan and aliskiren
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subject taking combination of valsartan and aliskiren.
Study: NCT01252238
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taking Amlodipine as prescribed by MD for management of high blood pressure.
Study: NCT00862888
Drug: PF-00446687
Normalized name: PF-00446687
DrugBank: PF-00446687 (DB12517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200mg dose as an oral solution
Study: NCT00862888
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose 100 mg tablet
Study: NCT00862888
Drug: PF-00446687
Normalized name: PF-00446687
DrugBank: PF-00446687 (DB12517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 125 mg dose as an oral solution
Study: NCT00862888
Drug: PF-00446687
Normalized name: PF-00446687
DrugBank: PF-00446687 (DB12517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 175 mg dose as an oral solution
Study: NCT00862888
Drug: PF-00446687
Normalized name: PF-00446687
DrugBank: PF-00446687 (DB12517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20 mg dose as an oral solution
Study: NCT01831531
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA \>1.6 m2) p.o bid d1-28
Study: NCT01216267
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lansoprazole 30 mg HS x 7 days
Study: NCT01216267
Drug: lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lanzoprazole 30 mg HS for 7 days
Study: NCT04336488
Drug: Matrix Metalloproteinase Inhibitors (Orochem)
Normalized name: Matrix
DrugBank: Matrix-M (DB16369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
Study: NCT01317420
Drug: BI 836845
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion once every three weeks
Study: NCT01275547
Drug: s-ketamine & midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
Study: NCT01275547
Drug: Morphine PCA
Normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg Morphine i.v. all 12 minutes as a patient controlled system
Study: NCT02718950
Drug: Liraglutide 3.0 mg
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will use liraglutide 3.0 mg for 2 weeks
Study: NCT00492466
Drug: Interferon-beta-1a
Normalized name: Interferon-beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage and frequency as per label
Study: NCT00492466
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage and frequency as per Biogen Idec protocol
Study: NCT00479401
Drug: Pramipexol Extended Release
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00479401
Drug: Pramipexol Immediate Release
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04564040
Drug: Acalabrutinib Treatment A
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg AT suspension in water via NG tube.
Study: NCT04564040
Drug: Acalabrutinib Treatment B
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
Study: NCT04564040
Drug: Acalabrutinib Treatment C
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
Study: NCT04564040
Drug: Acalabrutinib Treatment D
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg AT orally.
Study: NCT00020332
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04171986
Drug: Mecapegfilgrastim
Normalized name: Mecapegfilgrastim
DrugBank: Mecapegfilgrastim (DB19147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
Study: NCT03457337
Drug: S-1 plus Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
Study: NCT03457337
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib: 250mg, 1 day, orally
Study: NCT01721967
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03296553
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
Study: NCT03672539
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00298025
Drug: Recombinant human follicle stimulating hormone (r-hFSH)
Normalized name: Recombinant human follicle stimulating hormone beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
Study: NCT00298025
Drug: Human Menopausal Gonadotropin (hMG)
Normalized name: Human menopausal gonadotropin (urine derived)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
Study: NCT03672539
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03217942
Drug: NGF
Normalized name: Hemoglobin Shuangfeng
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT02374398
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm/group descriptions
Study: NCT00020332
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03809793
Drug: Acipimox 250 MG
Normalized name: acipimox 250 MG
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
Study: NCT00046891
Drug: Ginkgo Biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 120 mg per day (60 mg BID)
Study: NCT00470912
Drug: sunscreen RV 2547C
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002988
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002988
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00095680
Drug: SCIO-469 and bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
Study: NCT02722096
Drug: Axillary block anesthesia with Ropivacaine and Lidocaine
Normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
Study: NCT00141531
Drug: Apaziquone
Normalized name: Apaziquone
DrugBank: Apaziquone (DB12593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis.
Study: NCT03612401
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-3 adenoreceptor agonist
Study: NCT01521767
Drug: tolterodine tartrate
Normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg single dose of extended release capsules
Study: NCT01521767
Drug: tolterodine tartrate
Normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg single dose of microspheres in powder blend
Study: NCT02194231
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
Study: NCT02722096
Drug: Local anesthesia with Ropivacaine and Lidocaine
Normalized name: Doloracin with Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
Study: NCT02259790
Drug: Telmisartan/amlodipine fixed-dose combination tablet
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02259790
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02259790
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03914404
Drug: γ-linoleic acid and placebo(Thioctic Acid)
Normalized name: Linoleic acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time.
Study: NCT03914404
Drug: Thioctic Acid and placebo(γ-linoleic acid)
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time.
Study: NCT01864772
Drug: Carbo, 5FU, Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity
Study: NCT01846624
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01517568
Drug: liraglutide [3H]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 0.75 mg will be given as a subcutaneous injection
Study: NCT05535595
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perindopril 4 mg/d without genotyping
Study: NCT00368238
Drug: Recombinant human erythropoietin alfa (drug)
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00368238
Drug: Aspirin (drug)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00368238
Drug: Clopidogrel (drug)
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00558519
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00558519
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00558519
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00558519
Drug: pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00558519
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00558519
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00170963
Drug: valsartan/amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03839940
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as mouthwash
Study: NCT03839940
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard of care
Study: NCT01846624
Drug: Midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00000420
Drug: Ortho-Novum 777
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02204683
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal aflibercept
Study: NCT02875067
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03367299
Drug: Chemotherapy + Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
Study: NCT02818920
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications
Study: NCT00411281
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given subcutaneously
Study: NCT00995332
Drug: Cytarabine, all-trans retinoic acid, valproic acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
Study: NCT04019873
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
Study: NCT04019873
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
Study: NCT04019873
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
Study: NCT01794364
Drug: PF-06291874
Normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
Study: NCT04195945
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04195945
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04368663
Drug: Japanese traditional medicine group
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
Study: NCT03439293
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsule.
Study: NCT04195945
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04195945
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00803218
Drug: Fluticasone Propionate 0.005% Ointment-Reference Product
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Small amount applied and evaluated over the course of one day